Search results
Showing 481 to 495 of 914 results for death
Thoracoscopic epicardial radiofrequency ablation for atrial fibrillation (IPG286)
Evidence-based recommendations on thoracoscopic epicardial radiofrequency ablation for atrial fibrillation. This involves using heat to destroy the selected areas of the heart to prevent the occurrence or conduction of abnormal electrical activity.
View recommendations for IPG286Show all sections
Sections for IPG286
Evidence-based recommendations on cryotherapy for the treatment of liver metastases. This involves using cold temperatures applied through a special needle to destroy the cancer cells.
View recommendations for IPG369Show all sections
Sections for IPG369
Percutaneous atherectomy of femoropopliteal arterial lesions with plaque excision devices (IPG380)
Evidence-based recommendations on percutaneous atherectomy of femoropopliteal arterial lesions with plaque excision devices. This involves using a special cutting device to remove excess debris inside diseased blood vessels.
View recommendations for IPG380Show all sections
Sections for IPG380
Deep brain stimulation for intractable trigeminal autonomic cephalalgias (IPG381)
Evidence-based recommendations on deep brain stimulation for intractable trigeminal autonomic cephalalgias. This involves delivering electrical impulses to a precise area of the brain using an electrode to mask the pain.
View recommendations for IPG381Show all sections
Sections for IPG381
Irreversible electroporation for treating liver metastases (IPG445)
Evidence-based recommendations on irreversible electroporation for the treatment of liver metastases. This involves using very short electrical field pulses delivered over several minutes to destroy the tumour and a small surrounding tissue margin.
View recommendations for IPG445Show all sections
Sections for IPG445
Photodynamic therapy for early-stage oesophageal cancer (IPG200)
Evidence-based recommendations on photodynamic therapy for early-stage oesophageal cancer. This involves injecting a photosensitising agent into the tumour which is then activated by a light to destroy the tumour cells.
View recommendations for IPG200Show all sections
Sections for IPG200
Fetal cystoscopy for the diagnosis and treatment of lower urinary outflow tract obstruction (IPG205)
Evidence-based recommendations on fetal cystoscopy for the diagnosis and treatment of lower urinary outflow tract obstruction. This involves inserting a tube with a flexible camera through small cuts in the mother's abdomen to identify and open any blockage.
View recommendations for IPG205Show all sections
Sections for IPG205
Endoscopic saphenous vein harvest for coronary artery bypass grafting (IPG494)
Evidence-based recommendations on endoscopic saphenous vein harvest for coronary artery bypass grafting. This involves removing the vein under endoscopic guidance through a small cut near the knee (keyhole surgery).
Prevention of recurrence of C3 glomerulopathy post-transplant: eculizumab (ESUOM44)
Summary of the evidence on eculizumab to prevent the recurrence of C3 glomerulopathy post-transplant to inform local NHS planning and decision-making
However, EUS carries a small but significant risk of patient harms, including death. There is insufficient evidence available to...
This guideline covers care for people with a family history of breast, ovarian or another related (prostate or pancreatic) cancer. It aims to improve the long-term health of these families by describing strategies to reduce the risk of and promote early detection of breast cancer (including genetic testing and mammography). It also includes advice on treatments (tamoxifen, raloxifene) and surgery (mastectomy).
Evidence-based recommendations on nintedanib (Ofev) for treating idiopathic pulmonary fibrosis in adults when forced vital capacity is above 80% predicted.
Obinutuzumab with bendamustine for treating follicular lymphoma after rituximab (TA629)
Evidence-based recommendations on obinutuzumab (Gazyvaro) with bendamustine for follicular lymphoma that has not responded or has progressed up to 6 months after treatment with rituximab or a rituximab-containing regimen in adults.
Evidence-based recommendations on neratinib (Nerlynx) for extended adjuvant treatment of hormone receptor-positive, human epidermal growth factor receptor 2 (HER2)-positive early stage breast cancer in adults.
Omalizumab for treating severe persistent allergic asthma (TA278)
Evidence-based recommendations on omalizumab (Xolair) for treating severe persistent allergic asthma in people aged 6 and over.